1072
PŘEHLEDOVÉ42522701004388130181216258306358404446
ČLÁNKY88722701003973122176223272
JAK42533701001659104
inhibice5463370100145289105143158188222
v784337010035
léčbě8363370100145081119155
zánětlivých100733701003166104140167183198235273303341
revmatických13643370100235894155190216232263297335365403
onemocnění178333701003876111171210241279314352367
18819922701002869111
|350227010018
VNITŘNÍ4268043010746106127172220280301
LÉKAŘSTVÍ748804301074185130188236280325378400
/11948043010731
Vnitř1270804301074693112140166
Lék.1456804301074083122140
2023;69(3):181-1881615804301074487129173186232274298341362376414452493516554593638
/22988043010732
www.casopisvnitrnilekarstvi.cz442680430107651332012142542953293774274464795215705896176436927117307748128548809159449871007102310631101
12.425553085366883
Taylor522554083336091107145167
PC.702554083357589
Clinical803554083405570108123155188203
efficacy101955408334527088120153185218
of12505540833857
launched1320554083154784122154192227267
JAK1600554083246499
inhibitors1712554083145290105144160182219240268
in19935540831452
rheumatoid2058554083215994132189222243280296334
arthritis.2405554083325378116137153175190216230
Rheuma‑26485540833573108146204236258
tology425654083225974113152184
(Oxford).625654083186496117155176215234245
2019;58(Suppl8856540833569100131143179213232263301340380395
1):i17-i26.129665408334486075107137155171205239252
13.425753085366883
Biggioggero524754083355189128144182221260295316354
M,8937540835568
Becciolini9777540833570103134149187203218255270
A,12637540834155
Crotti1334754083406198120144159
C,15097540834053
Agape15777540834179112151186
E,17797540833346
Favalli1840754083336294127142157172
EG.2028754083327690
Upadacitinib21347540834482115155187219234257272310325364
and25137540833270109
filgotinib:263875408317344988126148163201216255268
the425854083226095
role535854083215874109
of6608540833756
JAK17328540832464100131
selective879854083266177111144168184216250
inhibition1145854083155391106145160183198236274
in14358540831553
the1503854083226095
treatment1614854083214377109131189224262283
of19138540833757
rheumatoid1985854083215994132190222244281297335
arthritis.2336854083325378116137153175190216230
Drugs25828540834567105144170
Con‑27688540834077115137
text.425954083225587111125
2019;8:212595.5659540833468100130143178190226257287322354388400
14.4251053085366985
Šenolt53110540833368107145161184
L,73610540833145
Mann80210540835587126164
H,98710540834457
Závada106510540833871103137176209
J,129410540832537
Pavelka13521054083356799134149180213
K,158610540833550
Vencovský165710540833669107140177209237267301
J.197910540832437
Doporučení203610540834685125164186225257291329345
České240110540834175102132167
revmatolo‑25881054083215588147180202239255294318
gické4251154083395587118154
společnosti60011540832666106123159192231271298322338
pro95911540834062100
farmakoterapii10811154083185374134168199237260295317351391407423
revmatoidní15251154083215689149182205243259299338354
artritidy19001154083325480102118141157197230
2017.215111540833570103133140
Česká231211540834175103134168
revmatologie.25021154083215689149182205243259298339355390403
2017;25(1):3-18.42512540833468100129139174209227258273285320342373404417
15.4251353085366883
Taylor5211354083336091107145167
PC.7011354083357589
Clinical8031354083395569107122154187202
efficacy1018135408334537088120153185219
of125013540833756
launched13191354083154785123155193227267
JAK15991354083246499
inhibitors17111354083155391106145160183219241268
in199213540831553
rheumatoid20581354083205994131189221243280295334
arthritis.24051354083325378116137152175190216229
Rheuma‑264713540833674109147204237259
tology4251454083225974113152184
(Oxford).6251454083186496117155176215234245
2019;58(Suppl88514540833569100131143179213232263301340380395
1):i17-i26.1296145408334486075107137155171205239252
16.4251553085366985
Strand5261554083325475108146185
V,72715540833645
Lee78815540833165101
EB,9051554083326880
Fleischmann1002155408332478197123155193251283321359
R,137715540833549
et144215540833457
al.15151554083324760
Tofacitinib15911554083336786119151166189204242257296
versus19031554083326688115152178
methotrexate209715540835893115153192213235269300333355389
in250215540831452
rheumatoid25701554083215994132190222244281297335
arthritis:4251654083325378116137152175190216229
patient‑reported6681654083387193108143181203222244279318357378403437476
outcomes11581654083377598129166224259286
from14581654083184077136
the16081654083215994
randomised17161654083215492131169227243269304343
phase207316540833977110136171
III22581654083153045
ORAL231716540834784127158
Start24891654083335487108132
trial.2635165408322435991106119
RMD276816540833691137
Open42517540834787122160
2016;2:e000308.60117540833468100131143178191225261297333366401436450
17.4251853085366876
Keystone51518540833569101128151188226261
EC,7901854083337386
Taylor8901854083326091107145167
PC,10711854083357588
Tanaka11731854083336199131161195
Y,138118540833644
et143918540833456
al.15091854083314760
Patient‑reported15831854083356788104138176198218240274313352373398432471
outcomes20681854083377598129166224259286
from23671854083194178136
a2517185408332
phase256318540833877109136171
32748185408334
stu‑27961854083264987109
dy42519540833870
of51019540833756
baricitinib5811954083387192108140155177193231246285
versus8801954083326687115152178
placebo10731954083385486119152192230
or131819540833759
adalimumab139119540833271103119134191229287319358
in176419540831452
rheumatoid18311954083215994132190222244281296335
arthritis:21801954083325378116137153175191217229
secondary24241954083266194130169208240261295
analy‑273419540833270102117149171
ses4252054083266188
from5282054083194178136
the6802054083215994
RA‑BEAM79020540833578100137170213268
study.10742054083264987126158168
Ann125720540834179117
Rheum139020540833573108146204
Dis16092054083466187
2017;76:1853_61.171220540833468100129139172203216246277311344380416446456
18.4252153085366985
Rubbert‑Roth52221540833573111151186207231251288325347385
A,92021540834054
Enejosa98721540833270105120157184217
J,121621540832436
Pangan126521540833566104143175213
AL,14902154083417386
et158921540833355
al.16572154083324760
Trial1729215408333506597112
of185421540833756
Upadacitinib192321540834382114153185217232254269307322360
or229621540833758
Abatacept236721540834180113134167199232271293
in267221540831553
Rheu‑273721540833573108146168
matoid42522540835790111148164203
Arthritis.6432254083416287125146162184200226239
N898225408344
Engl95822540833270109124
J1098225408324
Med.113722540835590129142
2020129522540833468101135
Oct144522540834780104
15;383(16):1511-1521.15642254083346475110145179197228259277289319349380408427457487521552561
19.4252353085366982
Ochi52223540834780118133
S,66923540833345
Sonomoto72923540833271109148206244266303
K,104723540833449
Nakayamada111123540834477107140171204262294333366
S,149123540833345
Tanaka15512354083336199131161195
Y.176023540833544
Preferable18192354083355589109143164197236252287
outcome21212354083377598128165224259
of239423540833757
Janus24652354083245795132158
kinase26382354083304684116143178
in‑28302354083155376
hibitors4252454083385392107130167188215
for6582454083185677
a752245408332
group8012454083396097135174
of99224540833857
difficult‑to‑treat1066245408338537290108140178193215235257294318340362396427449
rheumatoid15322454083216095132190223244281297335
arthritis18852454083315377115137152175190216
patients:21182454083397294109144182203231243
from23792454083184077136
the25322454083226095
FIRST26442454083324783116151
Re‑28122454083357093
gistry.4252554083385379103124158168
Arthritis6082554083416387125147162185200226
Res8492554083367198
Ther.96225540833272107128138
2022;24(1):61.111625540833468101135148183215234266280292328358367
20.4252653085367186
Smolen52326540833289127142176214
JS,7492654083245668
Landewé83026540833164101140174224258
RBM,110126540833571125138
Bergstra12512654083357091128154177198230
SA,14942654083327286
et159226540833456
al.16602654083324759
EULAR173226540833275106149184
recommendations19292654083205386122179237271309347379400415452490516
for24582654083185576
the25462654083225994
manage‑265226540835789126158197231253
ment42527540835792130152
of59427540833756
rheumatoid6672754083215994132190222244281297335
arthritis10192754083325378116137153175190217
with12522754083516789127
synthetic13962754083265998119157192215230262
and167527540833169109
biological18002754083395593108147186201233266282
disease‑modifying20982754083385480115147173208231290328368383402436452490529
antirheu‑26442754083327091107128166201239261
matic42528540835790111127159
drugs:5992854083385998137163175
202279028540833468101135
update.94128540833776116148170203216
Ann117228540834179117
Rheum,130428540833674109147205217
DiS.15372854083456193106
2023;82(1):3-18.165928540833468101135147182216233265279291326348379410423
21.4252953085367082
Pombo‑Suarez52529540833572130169208232263300333354388417
M,96029540835468
Sanchez‑Piedra104529540833366104136174209238260297311346386407440
C,150229540834053
Gómez‑Reino157329540834382140175205227264299314352390
J,198129540832436
et203429540833457
al.21082954083324760
After21862954083415984118139
JAK23432954083246499
inhibitor24602954083155290106145160183220241
failure:2719295408318516782119140174187
to42530540832259
cycle5003054083316496111146
or66230540833759
to73730540832259
switch,8123054083267893116146184197
that10253054083226092114
is115530540831541
the12123054083226095
question132330540833876110137160176214252
–1591305408335
data16423054083387193125
from17833054083194178136
the19363054083215994
JAK‑pot204630540832565100120160199220
collaboration2283305408331688499131170209231264285301339377
of267630540833757
regis‑27493054083205594109135156
tries.425315408322435993120134
Ann57431540834179117
Rheum,70731540833573108146204217
DiS.9393154083456193106
2023106131540833468101136
Feb;82(2):175-181.121231540833266106118153187204238256268298327360382412443475485
22.4253253085367388
Raychaudhuri5343254083356899131169202239279317354376391
SK,9463254083336782
Abria104932540834180102118150
C,121932540834154
Raychaudhuri12933254083366999131169202239279317355376392
SP.17053254083336873
Regulatory179932540833570110148163195217254276310
role21303254083215874109
of226032540833756
the23373254083226095
JAK245332540832464100
STAT257332540833367105134
kinase27273254083304684117144179
signalling4253354083264180118150166181196234273
system7183354083265986109143201
on93933540833776
the10353354083226095
IL-23/IL-171150335408315476293128152168200215246275
cytokine14463354083316489126157173211246
axis17123354083326479105
in183833540831452
psoriatic191133540833865103125141173194210242
arthritis.21733354083325378116137153175190217230
Ann242333540834180118
Rheum,256133540833574109147204217
DiS.27993354083456093106
2017;76(10):e36.42534540833468100129139172204223255286304316351385420433
23.4253553085367287
Mease52535540835489121148183
P,72135540833539
Hall7733554083447792107
S,89335540833345
FitzGerald9513554083334870101146182203236251290
O,125435540834758
et132535540833456
al.13943554083324760
Tofacitinib14673554083336786119151166189204242257296
or177635540833759
Adalimumab184835540834179111126141199237294327366
versus22273554083316687114151177
Placebo24173554083365082115148187226
for26563554083185678
Psori‑27473554083356199121136158
atic4253654083325469101
Arthritis.5413654083416287125146162184200226239
N796365408344
Engl85636540833270109124
J996365408324
Med.103536540835590129142
2017;377(16):1537-1550.119336540833468100129139174206241257289320338350380410443475493524554587621633
24.4253753085367186
McInnes52937540835487102140178213240
IB,7873754083155063
Anderson86837540834179119153175202240279
JK,11653754083246074
Magrey125737540835587126148182213
M,148837540835568
et157437540833457
al.16493754083324760
Trial1727375408333506698113
of185837540833757
Upadacitinib193337540834483116155187219234257272310325364
and231537540833270109
Adalimumab244237540834180112127142200238295328367
for28273754083185678
Psoriatic42538540833561100121137169191206238
Arthritis.6783854083416287125146162184200226239
N933385408344
Engl99338540833270109124
J1133385408324
Med.117238540835590129142
2021;384(13):1227-1239.133038540833468101132141176210246266297327345356386416451484502533563598631642
25.4253953085367387
Gladman5333954083446092131189222260
D,81339540834657
Rigby8903954083365190129161
W,107139540835867
Azevedo115939540834172106139173213251
VF,14303954083367076
et152639540833457
al.16033954083324760
Tofacitinib16843954083326786119152167189205243258297
for20023954083185677
Psoriatic210039540833561100121137169191206238
Arthritis23593954083416287125146162185200226
in260539540831553
Patients26793954083356789104139177199226
with4254054083516689127
an56740540833270
Inadequate6524054083155385124159199236269290324
Response9914054083367198137175214240275
to128240540832158
TNF135540540833379112
Inhibitors.14824054083155391106145161183220242269283
N1780405408345
Engl184040540833371110125
J1980405408324
Med.202040540835489129142
2017;377(16):1525-1536.217740540833468100130139174206241257289320338350380410443478500531561594628642
26.4254153085357085
Mease52341540835488119145179
PJ,7144154083355365
Lertratanakul7914154083316485109130162183215252284313350365
A,116841540834154
Anderson123441540834178116150171197235272
JK,15184154083245973
et160341540833455
al.16704154083324659
Upadacitinib174141540834381113151183214229251265302317355
for21084154083185576
psoriatic219641540833864102123138169190205236
arthritis24444154083315276113134149170185211
refracto‑2667415408320537293125157180216239
ry42542540832155
to49542540832259
biologics:5694254083395492108146186201233260273
SELECT‑PsA8574254083336596130170206224261287329
2.120142540833447
Ann126342540834179117
Rheum,139642540833573108146204217
DiS.16284254083456193106
2020;80(3):312-20.175042540833468101135148183218238272289301336367397417448482495
27.4254353085367079
van51743540833164101
der6314354083387293
Heijde7374354083437893108146181
D,93043540834556
Gladman9984354083445991130187219257
DD,126743540834591101
FitzGerald1381435408332476999144179200233248286
O,168043540834657
et175043540833455
al.18184354083324759
Radiographic189043540833567106121158197218251289328342374
Progression22764354083355693132152186213239253291329
According261743540834172103139160198213250289
to42544540832259
Baseline5024454083356895130146160198233
C‑reactive7544454083405375109141173198213245280
Protein10524454083355693115149164202
Levels12724454083326698132148174
and146544540833169108
Other159244540834770109144165
Risk17754454083365177107
Factors19014454083326194118155176204
in212344540831553
Psoriatic219444540833561100121137169191206238
Arthritis24504454083416387125147162185200226
Treated26944454083335084116138172211
with4254554083516689127
Tofacitinib5674554083336786119152167189204242257296
or87945540833759
Adalimumab.95345540834179111127142200237295327367379
J1347455408325
Rheumatol.138745540833574109146204237258295311324
2019;46(9):1089-1096.172645540833569100131143178214233266284296325357392427450481512548583596
28.4254653085367288
McInnes53346540835487102140178213240
IB,7934654083155063
Kato8764654083356991128
K,102446540833549
Magrey109446540835487126147181212
M,132746540835467
et141546540833456
al.14914654083324760
Upadacitinib157146540834483116155188220235257273310325365
in195646540831452
patients20294654083387193108143181203230
with22804654083506688126
psoriatic242746540833865103125140172194209241
arthritis26894654083315377115136152175190216
and42547540833270109
an55147540833270
inadequate6384754083145284123158198235268289323
response9784754083215582121159198224259
to125447540832259
non‑biological133047540833776114136176192230246284324339371404419
therapy:17664754083226095116149188219233
56-week20164754083346892144178213244
data22774754083387092125
from24194754083184077136
the25714754083226095
phase268347540833977110136171
32871475408334
SELECT‑PsA4254854083326596129170205224261287329
1769485408334
study.8184854083265088127159169
RMD100248540833591137
Open.115448540834787122160174
2021;7(3):e001838.134348540833468101133141174190224241253287323359391422456490504
29.4254953085357083
Gossec52049540834381107132166198
L,73049540833144
Baraliakos7864954083356787119134148179208245271
X,106949540833750
Kerschbaumer11314954083346888114146183221253289346380400
A,154349540834154
et160949540833355
al.16764954083314658
EULAR174649540833274105147182
recommendations19404954083215485121178235269306344375396411448485511
for24634954083185475
the25504954083215993
manage‑265449540835788125157195229251
ment42550540835792130152
of59050540833757
psoriatic66050540833865103125140172194209241
arthritis9145054083325378116137153175191217
with11445054083506688126
pharmacological128350540833978110131190222254291307345385400432464480
therapies:17765054083226095116149188204238265278
2019206750540833468100130
update.221050540833776116148170203216
Ann243950540834179117
Rheum,256950540833573108146204217
DiS.27995054083456193106
2020;79(6):700-712.42551540833468101135148181214233267285297330363399423454487517529
30.4255253085367287
Coates53152540834077110132165192
LC,7425254083317083
Soriano8445254083327192108140178216
ER,10795254083336882
Corp11805254083407798138
N,133752540834558
et141352540833457
al.14895254083314760
GRAPPA156852540834379122158193230
Treatment18175254083335084116137196231269290
Recommendations212652540833671103140198256291329368401422438476514541
domain268552540833977135167182220
subcommittees.42553540832663102135172230288303326350384419446460
Group90553540834365102140179
for11045354083195678
Research12025354083357097132164185216254
and147653540833270109
Assessment16055354083406895130157183241276314336
of196153540833756
Psoriasis203753540833561100121137169195210236
and229353540833270109
Psoriatic242253540833561100121137169190206238
Arthritis26805354083416287125146161184199225
(GRAPPA):4255454083186196139174209246264276
updated71454540833775115147168201241
treatment9675454083224377108130187222260281
recommendations12615454083205486123180238272310349381402417455493519
for17935454083185576
psoriatic188254540833865103124139171193208239
arthritis21345454083315277114135151173188214
2021.236054540833468101132141
Nat25135454083457798
Rev262454540833570102
Rheu‑273854540833573108145167
matol.42555540835790111148164177
2022;18(8):465-47961855540833468101135148178209228262280292326362396418455487520
31.3047553085366981
Maksymowych31455540835487117146179237276327361392430
WP,3591554083589498
van37065540833164102
der3824554083387394
Heijde3935554083447994109148183
D,41345540834556
Baraliakos4206554083356890123138153185215253279
X,45015540833952
et45695540833456
al.4641554083324860
Tofacitinib4718554083326685119151166189204242257296
is50305540831541
associated5087554083325885123156171203224258298
with5401554083506688127
attainment3047654083325478111126164221257295316
of33826540833756
the3457654083226095
minimally35706540835873111126183216231246278
important38676540831472111150172196229267289
reduction4174654083215594132164188204242280
in44736540831452
axial4544654083326379111126
magnetic46896540835789128166201224239271
resonance4979654083205481119158190228260294
imaging52926540831472104143159196235
inflammation304775408315527087119176234266288303340379
in34397540831452
ankylosing3504754083316999133149187213228266305
spondylitis38217540832665104142181213229244266281307
patients.4141754083387193108142180202229243
Rheumatology43977540833573108145203235257294309347387419
(Oxford).4828754083196597118155176214234245
2018;57(8):13901399.50867540833467991301421772102262602782903193493824183047854083346497133144
32.3047953085367186
Deodhar31529540834581119159197229250
A,34209540834155
Sliwinska‑Stanczyk3493954083334863114130168194224257280311332365403435466500531
P,40429540833539
Xu40999540833874
H,41919540834457
et42669540833456
al.4340954083324760
Tofacitinib4418954083336786119152167189205242257297
for4732954083195678
the4828954083226095
treatment4941954083214377109130189224262283
of52429540833757
ankylo‑53179540833169100133150188211
sing30471054083264179119
spondylitis:318610540832766105144183215232247269285311324
a3530105408332
phase358310540833978110137172
III,3776105408315304558
randomised,38551054083215492132170229244270306346358
double‑blind,423410540833877115155171206229269285301339378391
placebo‑controlled46461054083385587119153193232256289327365387409446462478513553
study.52191054083265088127160170
Ann540910540834280118
Rheum,304711540833574109146204217
DiS.32791154083466194107
2021;80(8):1004-1013.340111540833468101133141176211231265283295324356392428451482514545575588
33.30471253085367186
Navarro‑Compán315212540834577109142163184222245288325383422455493
V,366412540833645
Wei372712540835891106
JC,38521254083246578
Van394912540833667105
den407312540833873111
Bosch420212540833674101133171
F,439212540833238
et444912540833456
al.45241254083324760
Effect46031254083335271105138162
of478412540833756
tofacitinib48591254083225978111143159181196234249288
on516612540833776
pain,52611254083387186124137
fati‑5417125408318527389111
gue,304713540833876111123
health‑related318913540833772104119142180202224259274306328362401
quality361013540833875107123138160194
of382313540833757
life3899135408315304983
and400213540833169108
work413013540835088109140
productivity42891354083396098137175207231246279295317351
in465913540831553
patients47311354083387193108143181203231
with49811354083506688126
active51271354083316488103136170
ankylo‑531613540833270100134150188211
sing30471454083264179118
spondylitis:318414540832665104142181213229244266282308320
results35231454083215582119134157184
from37261454083184078136
a3881145408332
phase393114540833977110136171
III,4121145408315304558
randomised,41981454083205391130169227242268303343355
double‑blind,457214540833876115154170204227267283298336375388
placebo‑controlled49791454083385486119152192230254287324363384406443459474509548
trial.3047155408322435991106119
RMD318115540833691137
Open.333315540834787123161174
2022;8(2):e002253.352215540833469101136149184203237255267301337373406440475508521
34.30471653085367388
van315116540833265103
der32691654083387394
Heijde33791654083447994109148183
D,357716540834657
Song364916540833371109148
IH,38131654083155972
Pangan390016540833667105145177215
AL,41301654083417387
et423216540833456
al.43041654083324760
Efficacy4380165408332506886118151183216
and461216540833169109
safety47361654083265978113135169
of492016540833757
upadacitinib499216540833776109149181213228251266304319358
in536516540831553
pa‑54331654083397295
tients30471754083223873113135163
with32321754083516790129
active33831754083326590106139174
ankylosing357917540833271102137153193220235274314
spondylitis391517540832666106145185218235250273289316
(SELECT‑AXIS42521754083195285117152193230248291332348381
1):46541754083355062
a4737175408333
multicentre,479117540835897113136152185219258281303338350
randomised,51621754083215594134174233249276312352365
double‑blind,304718540833875113151167201224263279293331369382
placebo‑controlled,34411854083385486117150189227250283320357379400436452467501540552
phase400618540833876108134168
2/341871854083336094
trial.4293185408322435890105117
Lancet.442318540833164101133166188201
201946361854083346899129
Dec477718540834580112
7;394(10214):2108-2117.49011854083344478111146165196227260290321338350384415446481503533564592620626
35.30471953085367186
van315219540833265103
der32741954083387394
Heijde33871954083447994109148183
D,358919540834556
Deodhar366419540834581119159197229250
A,393319540834156
Maksymowych400719540835587118147179238276327361393431
WP,44571954083579398
et457419540833456
al.46491954083324760
Upadacitinib472819540834483116155187219234257272310325364
in511119540831553
active51831954083316488103136170
anky‑537219540833270100134156
losing3047205408315538095132171
spondylitis:323520540832665103142181213229244266282308320
results35712054083215582119135157185
of377220540833756
the38442054083226095
2-year,39552054083355587121153174184
double‑blind,415520540833877115154170205228268284299336376388
placebo‑controlled45592054083395587119153192231254288325363385406444460475510549
SELECT‑AXIS51242054083336596130170206224265306321353
15493205408334
study30472154083264987126158
and322121540833169108
open‑label334521540833777112150173189221260296312
extension.36722154083346590124162188203241279292
RMD398021540833590136
Open.413221540834787122160173
2022;8(2):e002280.432121540833468101136148183202236254266300336372405440474509521
36.30472253085367288
Deodhar315422540834581119159197229250
A,342322540834155
Van349722540833667105
den362122540833873111
Bosch375122540833574100132170
F,394022540833339
Poddubnyy399722540833672112151188228266297331
D,434722540834556
et442222540833456
al.44972254083324760
Upadacitinib457622540834382115154187219234256272310325364
for49592254083185677
the50552254083226095
treatment51692254083214377109130189224262283
of547122540833757
active30472354083326488103136170
non‑radiographic323623540833775114136158191230246283323344377416455470502
axial37562354083326479111127
spondyloarthritis390123540832665104142181213229267300322346384405421444459485
(SELECT‑AXIS44042354083195183114148188224242283324339371
2):47932354083345264
a4876235408331
randomised,49262354083215492131169227242268303343356
double­530023540833876114153169204227
‑blind,3047245408321617792130169181
placebo‑controlled,32442454083385486119152192230254287324363384406443459474509548561
phase382024540833978110136171
34007245408334
trial.4056245408322435991106119
Lancet.419024540833265103135169191205
2022;400(10349):369-379.441024540833468101136148183219255275306338371406440457469505539573597629661694705
37.30472553085367079
Ramiro314225540833568126141162199
S,335725540833245
Nikiphorou34172554083456090106145184222244281319
E,375125540833346
Sepriano381225540833368107129144176214252
A,408025540834155
et415025540833456
al.42212554083324860
ASAS‑EULAR429725540834175116150172207250282325361
recommendations46732554083215587124183240275314353385407422460498525
for52132554083185677
the53062554083216094
ma‑541625540835789112
nagement304726540833870109144202237275296
of335926540833756
axial34312654083316378110126
spondyloarthritis:357226540832665104142182213229268301322346385406421444459485498
2022408526540833468101136
update.423626540833776116148170204216
Ann446726540834179117
Rheum,460026540833574109146204217
DiS.48322654083456193107
2023;82(1):19-34.495426540833468101136147183216233265280291321351375407443455
38.30472753085367288
Harigai31512754083447698113152184199
M.336627540835569
Growing345027540834466103154169207246
evidence37122754083346682121156194226260
of398727540833857
the40602754083215994
safety41702754083265978113135169
of435427540833857
JAK44272754083246499
inhibitors45422754083145290105144160183219241268
in482627540831552
patients48942754083397294109144182203231
with51412754083506688126
rheuma‑52832754083215994132190222244
toid30472854083225974113
arthritis.31752854083325378116137153175190217230
Rheumatology342028540833674109147205237259296312350389421
(Oxford).38572854083186596117155177215234245
2019;58(Suppl411828540833468100130143178212231263300339379395
1):i34-i42.4528285408334496176109145168184219252264
39.30472953085367185
Riley31462954083355166101132
TR,32922954083337084
George338929540834480118140178213
MD.3616295408354100111
Risk37412954083365177107
for38622954083185677
infections39532954083155372106139163178216255281
with42482954083506688127
glucocorticoids43882954083385491123160193230251276291323360376415441
and484329540833169109
DMARDs4965295408346101143178225252
in523129540831452
patients52972954083397293109143181203231
with30473054083516689127
rheumatoid31893054083215994132190222244281296335
arthritis.35393054083325378116137153175191217230
RMD378530540833590136
Open.393730540834787122160173
2021;7(1):e001235.412630540833468101132141173190221236248282318354386416451484496
40.30473153085367489
Blum31523154083355189146
A,331531540834155
Adawi338731540834179111162177
M.358131540835468
Rheumatoid366631540833574109146204237258295311350
arthritis40323154083325378116137153175190216
(RA)42653154083195497116
and439831540833270109
cardiovascular45233154083326486124139177209242268301338354386407
disease.49473154083385379114146172207219
Autoimmun518331540834178101137153211268306344
Rev304732540833570103
2019;18(7):679–90.316532540833468100130143173204223258277289325358391428463499511
41.30473353085366981
Molander314833540835493109141179218253274
V,344233540833645
Bower350733540833574125159180
H,370733540834457
Frisell3784335408333526894129145160
T,396433540833341
Askling40253354083416999116131169208
J.425333540832436
Risk43093354083365177107
of443633540833857
venous451333540833266104142180207
thromboembolism47403354083216081118176215254290348387426442457483540
in530133540831452
rheu‑53733354083215994132154
matoid304734540835790111148164203
arthritis,32633454083325378116137153175190217230
and350634540833270109
its36283454083153865
association37073454083325885123156171203224240278316
with40373454083506688126
disease41773454083385379114146173208
activity:43983454083326488104136152174208222
a4633345408332
nationwide46783454083387092107145184234250289323
cohort501534540833168107145166191
study52203454083264987126158
from53913454083194178136
Sweden.304735540833282117156191229243
Ann330535540834179117
Rheum,343735540833674109147205217
DiS.36703554083456193106
2021379135540833569102133
Feb;80(2):169-175.393935540833367106118153189208242260272302333367390421451483495
42.30473653085367085
Ytterberg31453654083355680114135174209230268
SR,34263654083326781
Bhatt351936540833573105127151
DL,36833654083457790
Mikuls37863654083546999137152177
TR,39763654083326983
et407136540833456
al;41403654083314758
ORAL421136540834783125157
Surveillance43803654083337091125159174189204236273305338
Investigators.47313654083155283117144167182220252274310332359372
Cardiovascular51163654083397293131146183215248274306343358390411
and304737540833169107
Cancer316637540834072109141174194
Risk33733754083355075104
with34903754083506587124
Tofacitinib36263754083336685117149163185200237252290
in392937540831451
Rheumatoid399337540833472106143200232253289304342
Arthritis.43483754083406185122143158180195220234
N4594375408344
Engl465037540833270108123
J4785375408324
Med.482137540835488127140
2022;386(4):316-326.49733754083346799133145180213248266299316327362392422445477509541554
43.30473853085367186
Desai315238540834581107141156
RJ,33273854083356274
Pawar342038540833567117150171
A,361038540834155
Weinblatt368438540835790106143183199231252277
ME,398038540835487100
Kim409938540833552109
SC.42273854083327386
Comparative433238540834077135174207228261283299331365
Risk47163854083355177107
of484238540833756
Venous491738540833668107145183209
Thromboem‑51453854083337293130188228266302360382
bolism30473954083397995110137196
in326439540831453
Rheumatoid333839540833675111149208241263301317356
Arthritis37153954083426389127149165188204230
Patients39663954083366891106142181203231
Receiving421839540833671105139154188204242282
Tofacitinib45213954083336888122154170193209247263302
Versus48443954083367092119157184
Those504939540833373112139175
Receiving524539540833671105139155188204243282
Tumor304740540833366124163185
Necrosis325240540834581113135172199214241
Factor35134054083336295119156178
Inhibitors:37124054083145391106145161184221243270283
An401540540834180
Observational411540540834888115150171206239261277315354386402
Cohort453740540834078116155177201
Study.47594054083335492131164174
Arthritis49534054083416388126147163186201228
Rheumatol.520140540833674109147206238260297313326
2019;71(6):892-900.304741540833468100130143176208223257275287321356389409444480516529
44.30474253085367591
Molander315942540835594110143181221256278
V,345842540833645
Bower352442540833574126161183
H,372842540834457
Frisell3806425408333536995131147162
T,398942540833342
Delcoigne40524254083468297130167183223261297
B,436942540833649
Di443942540834662
Giuseppe45214254083456098125161200240277
D,481842540834657
Askling489642540834270100117132171210
J;512742540832537
ARTIS518542540834178112129161
study53674254083275089128161
group.30474354083386097136175188
Venous325643540833669107146184211
thromboembolism34874354083226182120179218257293352391430447462488546
with40544354083516789128
JAK420243540832565101
inhibitors43244354083145291106146161184221243271
and461543540833271110
other47464354083376098133155
immune‑modulatory492243540831472131169207242266325364404442457490512549571605
drugs:30474454083386098138164177
a3244445408332
Swedish329744540833383118158173199237
comparative355544540833169127167200222255277292325360
safety39354454083276079114137171
study41264454083265088128160
among430644540833291129168208
patients45344454083397294110145183205233
with47884454083506689127
rheumatoid49364454083216095133191224246283299338
arthritis.52954454083325378116138154176192218232
Ann304745540834179117
Rheum,317945540833674109147205217
DiS.34124554083456193106
2023;82(2):189-197.353445540833468101136147182216233267285297327358392416446476509516
45.30474653085367186
Benucci314846540833571109146178209224
M,338746540835468
Bernardini34694654083357192130163184222237275290
P,377346540833640
Coccia382846540833976109140155187
C,403046540833952
et409746540833456
al.41684654083314760
JAK42424654083246499
inhibitors43564654083155290106145160183220241268
and463946540833270109
autoimmune47624654083326992129144202260298336371
rheumatic51474654083215994132190222244259291
di‑54534654083385375
seases.30474754083266193120155181195
Autoimmun325747540834178101138153211269306344
Rev.361747540833570102112
2023374547540833468101136
Jan38964754083245694
14;22(4):103276.40054754083356678113147165198215227257288321354387419432
46.30474853085367287
Mease314548540835488118144178
PJ,33344854083345364
Deodhar340948540834579116155191222242
AA,36634854083408295
van376948540833163100
der38804854083387191
Heijde39834854083437791105143176
D,417148540834454
et423648540833455
al.43024854083324658
Efficacy4371485408332496784115147178210
and459248540833268106
safety47094854083265876109130163
of488348540833755
selective49494854083266074108139162177208241
TYK2520148540833270105141
inhibi‑53534854083145188102139154174
tor,3047495408321577886
deucravacitinib,314549540833771107138158190221252283297319333370384421432
in358949540831451
a3651495408331
phase369349540833976107132166
II387049540831529
trial3910495408322425687102
in402349540831451
psoriatic408549540833864101121136167187201232
arthritis.43284954083325275112132147168182207220
Ann455949540834177114
Rheum,468449540833572106143199211
DiS.49064954083455990103
2022;81(6):815-822.50204954083346698132143177208222254271282315346375395430462496507
47.30475053085367079
Frisell3141505408332526894129144159
T,331550540833342
Bower337250540833573124159180
H,356750540834457
Morin363950540835493114130168
M,382250540835467
et390450540833456
al.39755054083324760
ARTIS405050540834177111127160
Study42245054083335492131163
group.44025054083385996134173186
Safety46035054083326584119141175
of479250540833857
biological48645054083395492108146186201233266281
and516050540833270109
targeted52845054083215475113148170204244
synthetic30475154083265997119157192214230262
disease‑modifying33255154083395480115147173208231290328368383402437453490529
antirheumatic38715154083327092107128166201239297329351366398
drugs42865154083385998137163
for44665154083185677
rheumatoid45605154083205994132190222244281296335
arthritis49125154083315377115137152175190216
as514551540833158
used52205154083376398138
in537451540831553
cli‑5444515408331466183
nical30475254083375284117132
practice:31925254083385992124148163195228241
results34465254083205481117133155182
from36415254083184077135
the37895254083225994
ARTIS389652540834176110126158
programme.40675254083386097136157190247305340352
Ann443152540834179117
Rheum,456152540833573108145203215
DiS.47895254083456193106
2023:ard-2022-223762.490852540833467100135146178199237259289323356390411441476510542574607619
doi:30475354083387692104
10.1136/ard-2022-223762.31665354083346678109137167201226257278316338369403436471491522557592624656689702
Epub388353540833271110149
ahead404753540833270105137176
of423853540833757
print.43105354083396076114135149